Table 4.
Summary of key clinical trials in RRMM with DARA resistant/refractory patient subgroup.
| Trial | % DARA Refractory | ORR | PFS | OS |
|---|---|---|---|---|
| DREAMM-2 Belantamab Mafodotin |
100% | 32% | 2.8 months (95% CI: 1.6–3.6 months) | 13.7 months (95% CI: 9.9–NR) |
| DREAMM-3 BEL vs. POM-dex |
NT | 41% vs. 36% | 11.2 vs. 7 months (HR 1.03) | 21.2 vs. 21.2 months (HR 1.13) |
| MajesTEC-1 Teclistamab |
89.7% | 63% | 11.3 months (95% CI: 8.8–17.1 months) | 18.3 months (95% CI: 15.1-NE)* |
Abbreviations: DARA—Daratumumab, BEL—Belantamab Mafodotin, POM—Pomalidomide, dex—Dexamethasone, ORR—Overall Response Rate, PFS—Progression Free Survival, OS—Overall Survival, HR—hazard ratio, CI—Confidence Interval, NR—Not Reached, NE—Not estimable, NT—Not Tabulated. * Data not yet mature.